• Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharmaceuticals

AVANIR Pharmaceuticals Inc

+ Add to Watchlist


3.934 EUR 0.0000.00%

As of 02:16:15 ET on 07/25/2014.

Snapshot for AVANIR Pharmaceuticals Inc (AV2B)

Open: 3.859 Day's Range: 3.859 - 3.934 Volume: 0
Previous Close: 3.934 52wk Range: 1.901 - 4.500 1-Yr Rtn: +10.07%

Stock Chart for AV2B

No chart data available.
  • AV2B:GR 3.934
  • 1D
  • 1M
  • 1Y
Interactive AV2B Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for AV2B

Current P/E Ratio (ttm) -
Estimated P/E(09/2014) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (09/2014) -0.3220
Est. PEG Ratio -
Market Cap (M EUR) 673.06
Shares Outstanding (M) 171.09
30 Day Average Volume 434
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/06/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for AV2B

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for AV2B

AVANIR Pharmaceuticals Inc. develops, acquires, and markets treatments for central nervous system disorders, inflammation, and infectious diseases. The Company develops treatments for pseudobulbar affect, diabetic peripheral neuropathic pain, and other conditions. AVANIR out-licensed its moniclonal antibodies, and produces an over-the-counter treatment for cold sores.

Keith A KatkinPresident/CEORohan PalekarSenior VP/Chief Commercial Ofcr
Gregory J Flesher "Greg"Senior VP:Corporate Dev/Chief Bus OfcrJoao SiffertSenior VP:R&D/Chief Scientific Ofcr
More Company Profile & Key Executives for AV2B

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil